Showing 2681-2690 of 3223 results for "".
- LumiThera: Data Show Valeda Treatments Improve Vision and Retinal Function in Dry AMD patientshttps://modernod.com/news/lumithera-data-show-valeda-treatments-improve-vision-and-retinal-function-in-dry-amd-patients/2479408/LumiThera, a commercial stage medical device company offering a photobiomodulation (PBM) treatment for ocular damage and disease, announced the final topline data from the ELECTROLIGHT pilot study in intermediate dry AMD patients. A total of 23 eyes from 15 subjects with dry AMD were enro
- EyeMD EMR Healthcare Systems Introduces Edge Computinghttps://modernod.com/news/eyemd-emr-healthcare-systems-introduces-edge-computing-at-the-ascrs-annual-meeting/2479397/EyeMD EMR Healthcare Systems, a provider of Electronic Medical Records (EMR) software for ophthalmologists, announced it will be introducing Edge Computing at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Las Vegas. The Edge Computing Service is a featur
- Monty Montoya Appointed CEO of TherOptixhttps://modernod.com/news/monty-montoya-appointed-ceo-of-theroptix/2479395/Monty Montoya has been named chief executive officer of TherOptix, a preclinical biopharma company focused on delivering clinically impactful therapeutics via a drug-eluting contact lens platform. TherOptix has received orphan drug designation on its lead candidate (001) for prevention of prolife
- SpyGlass Pharma Appoints Industry Veteran Patrick Mooney as Chief Executive Officerhttps://modernod.com/news/spyglass-pharma-appoints-industry-veteran-patrick-mooney-as-chief-executive-officer/2479389/SpyGlass Pharma has appointed industry veteran Patrick Mooney as Chief Executive Officer. This appointment coincides with broad company expansion and relocation to new headquarters in Aliso Viejo, California. “We are excited to bring Patrick to
- Bausch + Lomb to Present 14 Scientific Posters Featuring New Analyses Involving its Surgical Technologies at ASCRS 2021https://modernod.com/news/bausch-lomb-to-present-14-scientific-posters-featuring-new-analyses-involving-its-surgical-technologies-at-ascrs-2021/2479382/Bausch + Lomb announced the presentation of 14 scientific posters involving the company’s ophthalmic surgical technologies at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will take place from July 23-27, 2021, in Las Vegas. “We are always pleased to
- ASCRS: Insurance Company Policy Delays Sight-Restoring Surgery, Puts Patients in Jeopardyhttps://modernod.com/news/ascrs-insurance-company-policy-delays-sight-restoring-surgery-puts-patients-in-jeopardy/2479334/The decision by Aetna to require preauthorization of all cataract surgery procedures went into effect July 1. In a news release, ASCRS said it is opposed to the preauthorization policy, stating it will create delays i
- Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149https://modernod.com/news/oxurion-nv-to-focus-resources-on-clinical-assets-thr-687-and-thr-149/2479325/Oxurion announced a restructuring plan aimed at better aligning resources towards executing its clinical development strategy, including advancing its two novel programs, THR-687 and THR-149, according to a company news release. Following a detailed review of its operations and gr
- Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, Byoovizhttps://modernod.com/news/samsung-bioepis-and-biogen-receive-positive-chmp-opinion-for-ranibizumab-biosimilar-byooviz/2479327/Samsung Bioepis Biogen announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Byooviz, a biosimilar candidate referencing Lucentis (ranibizumab), also known as SB11. Ranibizumab is an anti-VEGF (vasc
- Santen Receives FDA Approval for Verkazia for the Treatment of Vernal Keratoconjunctivitishttps://modernod.com/news/santen-receives-fda-approval-for-verkazia-for-the-treatment-of-vernal-keratoconjunctivitis/2479321/Santen announced that the FDA has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. VKC is a rare and recurrent allergic eye condition, most common in children and adolescents, that causes seve
- Tarsus Announces Positive Results of Saturn-1 Trial Evaluating TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-announces-positive-results-of-saturn-1-trial-evaluating-tp-03-for-the-treatment-of-demodex-blepharitis/2479309/Tarsus Pharmaceuticals announced that all pre-specified primary and secondary endpoints were met for its pivotal Phase 2b/3 Saturn-1 trial evaluating the company’s novel investigational therapeutic, TP-03 (lotilaner ophthalmic solution, 0.25%), in patients with Demodex blepharitis. Results demons